Jørgen B Jensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4477468/publications.pdf

Version: 2024-02-01

126708 123241 4,357 134 33 61 citations g-index h-index papers 138 138 138 6012 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Prospective versus retrospective recordings of comorbidities and complications in bladder cancer patients undergoing radical cystectomy $\hat{a} \in \hat{a}$ a randomized controlled trial. Scandinavian Journal of Urology, 2022, 56, 6-11.	0.6	4
2	Misinterpretation resulting in a diagnosis of bladder cancer – A case emphasising the value of diagnostic reconsideration. Urology Case Reports, 2022, 40, 101928.	0.1	1
3	A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013–2019. Scandinavian Journal of Urology, 2022, 56, 34-38.	0.6	3
4	The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer. Genome Medicine, 2022, 14, 8.	3.6	19
5	The transferability of the minimal invasive surgeon's skills to open surgery. Scandinavian Journal of Urology, 2022, 56, 131-136.	0.6	3
6	Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer. European Urology Oncology, 2022, 5, 203-213.	2.6	14
7	Reply to "Letter to the Editor― Detection rate of CIS during TURBT following shift from PDD to NBI in a single University Hospital. Urology, 2022, , .	0.5	0
8	Detection Rate of Carcinoma In Situ During TURBT Following Shift from Photodynamic Diagnosis to Narrow Band Imaging in a Single University Hospital. Urology, 2022, 161, 83-86.	0.5	5
9	Effect of a Smoking and Alcohol Cessation Intervention Initiated Shortly Before Radical Cystectomyâ€"the STOP-OP Study: A Randomised Clinical Trial. European Urology Focus, 2022, 8, 1650-1658.	1.6	14
10	Caveats in the diagnosis of suspected nonâ€endemic verrucous carcinoma in the urinary bladder. BJU International, 2022, 129, 457-459.	1.3	0
11	Optimal intervals for follow-up cystoscopy in non-muscle invasive bladder cancer: a systematic review regarding oncological safety. Scandinavian Journal of Urology, 2022, 56, 39-46.	0.6	3
12	Quality of life, voiding and sexual function of penile cancer patients: DaPeCaâ€10—a crossâ€sectional questionnaire survey. BJUI Compass, 2022, 3, 354-362.	0.7	4
13	PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity. Scientific Reports, 2022, 12, .	1.6	3
14	The discovery of bacterial biofilm in patients with muscle invasive bladder cancer. Apmis, 2021, 129, 265-270.	0.9	10
15	Male erectile function after treatment for colorectal cancer: a populationâ€based crossâ€sectional study. Colorectal Disease, 2021, 23, 367-375.	0.7	5
16	DaPeCaâ€7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer. BJU International, 2021, 127, 254-262.	1.3	12
17	Which data are available in central registries on bladder cancer patients in the five Nordic countries. Scandinavian Journal of Urology, 2021, 55, 135-141.	0.6	0
18	Patients with NMIBC with the highest risk of progression are correctly selected for cystectomy in Sweden. Scandinavian Journal of Urology, 2021, 55, 54-55.	0.6	0

#	Article	lF	CITATIONS
19	DaPeCa-8: drawing the map of lymphatic drainage in patients with invasive penile cancer – evidence from SPECT/CT and sentinel node surgery. Scandinavian Journal of Urology, 2021, 55, 383-387.	0.6	2
20	Complications after scrotal surgery – still a major issue?. Scandinavian Journal of Urology, 2021, 55, 404-407.	0.6	5
21	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 2021, 12, 2301.	5.8	159
22	Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non–muscle-invasive Bladder Cancer—A Randomized Controlled Trial. Eur Urol 2020;78:856–62. European Urology, 2021, 79, e137.	0.9	O
23	Genome-wide circulating tumor DNA monitoring for bladder cancer treatment management and organ preservation Journal of Clinical Oncology, 2021, 39, e16527-e16527.	0.8	O
24	Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients. Scandinavian Journal of Urology, 2021, 55, 281-286.	0.6	9
25	STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 438.e1-438.e9.	0.8	9
26	The devil is in the selected details: second-look resection in T1 bladder cancer. Scandinavian Journal of Urology, 2021, 55, 275-275.	0.6	0
27	Potential candidates for en bloc resection among patients with primary and recurrent bladder tumours. Scandinavian Journal of Urology, 2021, 55, 366-371.	0.6	0
28	Reply to: Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy. Nature Communications, 2021, 12, 4834.	5.8	3
29	Can maneuverability in the robot assisted laparoscopic stapler during ileoileal anastomosis compensate for shorter stapler length? – A randomized experimental porcine study. Scandinavian Journal of Urology, 2021, 55, 474-479.	0.6	0
30	The Inequality of Females in Bladder Cancer. Apmis, 2021, 129, 694-699.	0.9	8
31	Human papilloma virus prevalence in penile cancer: A multicenter study from Denmark (DaPeCaâ€6). International Journal of Urology, 2021, 28, 466-468.	0.5	1
32	Intraoperative Mitomycin C Bladder Installation During Radical Nephroureterectomy Is Feasible and Safe. European Urology Open Science, 2021, 34, 41-46.	0.2	4
33	SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer. European Urology Open Science, 2021, 34, 59-67.	0.2	1
34	Effects of lung protective ventilation on postoperative respiratory parameters in patients undergoing robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2020, 14, 509-516.	1.0	3
35	Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. European Urology Oncology, 2020, 3, 73-79.	2.6	29
36	Urinary tract infections and risk of squamous cell carcinoma bladder cancer: A Danish nationwide case–control study. International Journal of Cancer, 2020, 146, 1930-1936.	2.3	22

#	Article	IF	Citations
37	DaBlaCa-11: Photodynamic Diagnosis in Flexible Cystoscopy—A Randomized Study With Focus on Recurrence. Urology, 2020, 137, 91-96.	0.5	10
38	Intraoperative Adverse Incident Classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. European Urology, 2020, 77, 601-610.	0.9	75
39	A rare case of urothelial carcinoma with syncytiotrophoblastic cell differentiation. Scandinavian Journal of Urology, 2020, 54, 358-359.	0.6	O
40	The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non–muscle-invasive Bladder Cancer—A Randomised Controlled Trial. European Urology, 2020, 78, 856-862.	0.9	20
41	Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nature Communications, 2020, 11, 4858.	5.8	124
42	DaPeCa5 – obesity at the time of diagnosis does not predict poor cancer-specific survival in patients with penile squamous cell carcinoma – a Danish National study. Scandinavian Journal of Urology, 2020, 54, 420-425.	0.6	1
43	Optimal Delivery of Follow-Up Care After Radical Cystectomy for Bladder Cancer. Research and Reports in Urology, 2020, Volume 12, 471-486.	0.6	8
44	Clinical markers of morbidity, mortality and survival in bladder cancer patients treated with radical cystectomy. A systematic review. Scandinavian Journal of Urology, 2020, 54, 267-276.	0.6	3
45	Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential. Cells, 2020, 9, 1362.	1.8	20
46	Comment on: Cystoscopic surveillance of patients with non-muscle-invasive bladder cancer revisited. Scandinavian Journal of Urology, 2020, 54, 369-369.	0.6	0
47	Robot-assisted vesicovaginal fistula repair – initial experience. Scandinavian Journal of Urology, 2020, 54, 147-149.	0.6	5
48	Human papillomavirus and urinary bladder cancer revisited. Apmis, 2020, 128, 72-79.	0.9	19
49	Oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in Denmark. Scandinavian Journal of Urology, 2020, 54, 58-64.	0.6	9
50	Mutational Analysis of Field Cancerization in Bladder Cancer. Bladder Cancer, 2020, 6, 253-264.	0.2	12
51	Urinary diversion in the treatment of refractory bladder pain syndrome. Scandinavian Journal of Urology, 2019, 53, 424-430.	0.6	3
52	Emphysematous cystitis leading to bladder necrosis and acute cystectomy – report of a rare case with fatal outcome. Scandinavian Journal of Urology, 2019, 53, 439-440.	0.6	2
53	No Added Value of ¹⁸ F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy. Journal of Nuclear Medicine, 2019, 60, 1713-1716.	2.8	14
54	Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy. Scandinavian Journal of Urology, 2019, 53, 213-216.	0.6	4

#	Article	IF	CITATIONS
55	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology, 2019, 37, 1547-1557.	0.8	298
56	Perioperative management of radical cystectomy in the Nordic countries. Scandinavian Journal of Urology, 2019, 53, 51-55.	0.6	4
57	Clam augmentation enterocystoplasty as management of urge urinary incontinence and reduced bladder capacity. Scandinavian Journal of Urology, 2019, 53, 417-423.	0.6	1
58	Progress towards a Nordic standard for the investigation of hematuria: 2019. Scandinavian Journal of Urology, 2019, 53, 1-6.	0.6	14
59	Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up. European Urology Focus, 2019, 5, 90-96.	1.6	49
60	Implementing a Multimodal Prehabilitation Program to Radical Cystectomy in a Comprehensive Cancer Center: A Pilot Study to Assess Feasibility and Outcomes. Urologic Nursing, 2019, 39, 303.	0.1	10
61	Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups. Clinical Cancer Research, 2018, 24, 1586-1593.	3.2	79
62	Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Scientific Reports, 2018, 8, 1917.	1.6	50
63	Prehabilitation for major abdominal urologic oncology surgery. Current Opinion in Urology, 2018, 28, 243-250.	0.9	37
64	Validation of the Clavien–Dindo Grading System in Urology by the European Association of Urology Guidelines Ad Hoc Panel. European Urology Focus, 2018, 4, 608-613.	1.6	187
65	Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. European Urology, 2018, 73, 535-540.	0.9	112
66	Red patches during bladder cancer surveillance: to biopsy or not to biopsy?. Translational Andrology and Urology, 2018, 7, 280-282.	0.6	1
67	68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 579-585.	0.7	24
68	Evaluation of Hospital-Based Hematuria Diagnosis and Subsequent Cancer Risk Among Adults in Denmark. JAMA Network Open, 2018, 1, e184909.	2.8	16
69	A validated algorithm to identify recurrence of bladder cancer: a register-based study in Denmark. Clinical Epidemiology, 2018, Volume 10, 1755-1763.	1.5	11
70	Correlation between organ-specific co-morbidities and complications in bladder cancer patients undergoing radical cystectomy. Scandinavian Journal of Urology, 2018, 52, 395-400.	0.6	16
71	Human papillomavirus and squamous cell carcinoma of the urinary bladder: DaBlaCa-10 study. Scandinavian Journal of Urology, 2018, 52, 371-376.	0.6	11
72	Preadmission antidepressant use and bladder cancer: a population-based cohort study of stage at diagnosis, time to surgery, and surgical outcomes. BMC Cancer, 2018, 18, 1035.	1.1	2

#	Article	IF	Citations
73	Robot-assisted laparoscopic cystectomy with intracorporeal urinary diversion vs. open mini-laparotomy cystectomy: evaluation of surgical inflammatory response and immunosuppressive ability of CO ₂ -pneumoperitoneum in an experimental porcine study. Scandinavian Journal of Urology, 2018, 52, 249-255.	0.6	1
74	STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2018, 24, 4145-4153.	3.2	23
75	Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1884-1897.	3.3	76
76	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. European Urology, 2017, 71, 961-969.	0.9	154
77	Human papillomavirus types 44, 52, 66 and 67 detected in a woman with squamous cell carcinoma of the urinary bladder. Scandinavian Journal of Urology, 2017, 51, 85-86.	0.6	2
78	Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?. Scandinavian Journal of Urology, 2017, 51, 290-292.	0.6	15
79	Outcomes of haematuria referrals: two-year data from a single large university hospital in Denmark. Scandinavian Journal of Urology, 2017, 51, 282-289.	0.6	16
80	Comparison of White Light, Photodynamic Diagnosis, and Narrow-band Imaging in Detection of Carcinoma In Situ or Flat Dysplasia at Transurethral Resection of the Bladder: the DaBlaCa-8 Study. Urology, 2017, 102, 138-142.	0.5	30
81	Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Scientific Reports, 2017, 7, 395.	1.6	117
82	Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study. Scandinavian Journal of Urology, 2017, 51, 120-123.	0.6	15
83	Efficacy of preoperative uro-stoma education on self-efficacy after Radical Cystectomy; secondary outcome of a prospective randomized controlled trial. European Journal of Oncology Nursing, 2017, 28, 41-46.	0.9	29
84	Evaluation of robot-assisted laparoscopic versus open cystectomy and effect of carbon dioxide-pneumoperitoneum on histopathological findings in ureteroenteric anastomoses: results from an experimental randomized porcine study. Scandinavian Journal of Urology, 2017, 51, 50-56.	0.6	1
85	Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Scientific Reports, 2017, 7, 11702.	1.6	110
86	Postoperative C-reactive protein concentration and clinical outcome: comparison of open cystectomy to robot-assisted laparoscopic cystectomy with extracorporeal or intracorporeal urinary diversion in a prospective study. Scandinavian Journal of Urology, 2017, 51, 381-387.	0.6	15
87	Laparoscopic and robotic nephroureterectomy: does lymphadenectomy have an impact on the clinical outcome?. International Urology and Nephrology, 2017, 49, 1785-1792.	0.6	6
88	Perioperative Systemic Inflammatory Response following Robot-Assisted Laparoscopic Cystectomy vs. Open Mini-Laparotomy Cystectomy: A Prospective Study. Urologia Internationalis, 2017, 99, 436-445.	0.6	14
89	Asymptomatic microscopic hematuria as a predictor of neoplasia in the urinary tract. Scandinavian Journal of Urology, 2017, 51, 373-375.	0.6	8
90	Efficacy of commercialised extracorporeal shock wave lithotripsy service: a review of 589 renal stones. BMC Urology, 2017, 17, 59.	0.6	15

#	Article	IF	Citations
91	Prognostic Impact of a 12-gene Progression Score in Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. European Urology, 2017, 72, 461-469.	0.9	74
92	Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients. Oncotarget, 2017, 8, 99707-99721.	0.8	19
93	The Danish Bladder Cancer Database. Clinical Epidemiology, 2016, Volume 8, 439-443.	1.5	10
94	Extended versus superextended lymph-node dissection in radical cystectomy: subgroup analysis of possible recurrence-free survival benefit. Scandinavian Journal of Urology, 2016, 50, 175-180.	0.6	13
95	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. Cancer Research, 2016, 76, 5894-5906.	0.4	87
96	Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Molecular Oncology, 2016, 10, 1450-1460.	2.1	44
97	DaPeCaâ€3: promising results of sentinel node biopsy combined with ¹⁸ Fâ€fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph nodeâ€negative patients with penile cancer – a national study from Denmark. BJU International, 2016, 118, 102-111.	1.3	39
98	Exercise-based pre-habilitation is feasible and effective in radical cystectomy pathwaysâ€"secondary results from a randomized controlled trial. Supportive Care in Cancer, 2016, 24, 3325-3331.	1.0	73
99	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell, 2016, 30, 27-42.	7.7	486
100	DaPeCaâ€1: diagnostic accuracy of sentinel lymph node biopsy in 222 patients with penile cancer at four tertiary referral centres – a national study from Denmark. BJU International, 2016, 117, 235-243.	1.3	40
101	Penile cancer in Scandinavia: Current practice and future perspectives. Scandinavian Journal of Urology, 2016, 50, 90-92.	0.6	10
102	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. European Urology, 2016, 70, 75-82.	0.9	174
103	DaPeCa-2: Implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process – A comparative before-and-after study in a tertiary referral centre in Denmark. Scandinavian Journal of Urology, 2016, 50, 80-87.	0.6	10
104	Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: A prospective randomized controlled trial. Scandinavian Journal of Urology, 2015, 49, 133-141.	0.6	116
105	Evaluating sexual function in women after radical cystectomy as treatment for bladder cancer. Scandinavian Journal of Urology, 2015, 49, 463-467.	0.6	19
106	Occult distal urethral carcinoma presenting as metastatic carcinoma in the inguinal lymph nodes. Scandinavian Journal of Urology, 2015, 49, 79-80.	0.6	3
107	Multidisciplinary rehabilitation can impact on health-related quality of life outcome in radical cystectomy: secondary reported outcome of a randomized controlled trial. Journal of Multidisciplinary Healthcare, 2014, 7, 301.	1.1	53
108	Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. Annals of Oncology, 2014, 25, 877-883.	0.6	41

#	Article	IF	CITATIONS
109	High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. BMC Cancer, 2014, 14, 638.	1.1	24
110	Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties. Cancer Research, 2014, 74, 5758-5771.	0.4	237
111	Quality Assessment of Partial Nephrectomy Complications Reporting Using EAU Standardised Quality Criteria. European Urology, 2014, 66, 522-526.	0.9	23
112	Editorial Comment to Development and external validation of lymph node density cutâ€off points in prospective series of radical cystectomy and pelvic lymph node dissection. International Journal of Urology, 2012, 19, 1075-1075.	0.5	0
113	Expression of TIP60 (tatâ€interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatmentâ€specific outcome of localised invasive bladder cancer. BJU International, 2012, 110, E1228-36.	1.3	92
114	Evaluation of different lymph node (LN) variables as prognostic markers in patients undergoing radical cystectomy and extended LN dissection to the level of the inferior mesenteric artery. BJU International, 2012, 109, 388-393.	1.3	39
115	Extended versus limited lymph node dissection in radical cystectomy: Impact on recurrence pattern and survival. International Journal of Urology, 2012, 19, 39-47.	0.5	51
116	Flowâ€Evoked Vasodilation Is Blunted in Penile Arteries from Zucker Diabetic Fatty Rats. Journal of Sexual Medicine, 2012, 9, 1789-1800.	0.3	10
117	Lymph node dissection in bladder cancer. Impact on staging and prognosis. Danish Medical Journal, 2012, 59, B4559.	0.5	1
118	Mini″aparotomy approach to radical cystectomy. BJU International, 2011, 108, 1125-1130.	1.3	15
119	High Expression of Karyopherin-α2 Defines Poor Prognosis in Non–Muscle-Invasive Bladder Cancer and in Patients with Invasive Bladder Cancer Undergoing Radical Cystectomy. European Urology, 2011, 59, 841-848.	0.9	70
120	Incidence of occult lymph-node metastasis missed by standard pathological examination in patients with bladder cancer undergoing radical cystectomy. Scandinavian Journal of Urology and Nephrology, 2011, 45, 419-424.	1.4	12
121	Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer. Scandinavian Journal of Urology and Nephrology, 2011, 45, 436-443.	1.4	9
122	Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU International, 2010, 106, 199-205.	1.3	52
123	Size and volume of metastatic and non-metastatic lymph nodes in pelvis and lower abdomen in patients with carcinoma of the bladder undergoing radical cystectomy. Scandinavian Journal of Urology and Nephrology, 2010, 44, 291-297.	1.4	8
124	Sentinel lymphâ€node biopsy in patients with squamous cell carcinoma of the penis. BJU International, 2009, 103, 1199-1203.	1.3	35
125	Estimation of the true number of lymph nodes in lymphadenectomy specimens from radical cystectomy. Scandinavian Journal of Urology and Nephrology, 2009, 43, 288-292.	1.4	5
126	Laparoscopic pelvic lymph-node dissection in prostate cancer before external beam radiotherapy: Risk factors of nodal involvement and relapse following intended curative treatment. Scandinavian Journal of Urology and Nephrology, 2009, 43, 19-24.	1.4	1

#	Article	IF	CITATION
127	Terminal Patients With Urinary Diversion. Journal of Wound, Ostomy and Continence Nursing, 2009, 36, 424-427.	0.6	0
128	Non-Fournier's gangrene of the penis: Report of two cases and review of the literature. Scandinavian Journal of Urology and Nephrology, 2007, 41, 170-172.	1.4	0
129	Complications and neobladder function of the Hautmann orthotopic ileal neobladder. BJU International, 2006, 98, 1289-1294.	1.3	45
130	Clinical experience with the mentor alpha-1 inflatable penile prosthesis: Report on 65 patients. Scandinavian Journal of Urology and Nephrology, 2005, 39, 69-72.	1.4	14
131	Patient and partner satisfaction with the mentor alpha-1 inflatable penile prosthesis. Scandinavian Journal of Urology and Nephrology, 2005, 39, 66-68.	1.4	11
132	Recurrent urinary tract infection due to hernia mesh erosion into the bladder. Scandinavian Journal of Urology and Nephrology, 2004, 38, 438-439.	1.4	15
133	Pseudosarcomatous Fibromyxoid Tumor of the Prostate. Scandinavian Journal of Urology and Nephrology, 2003, 37, 85-87.	1.4	9
134	Subcutaneous Bleeding: First Sign of Prostate Cancer. Scandinavian Journal of Urology and Nephrology, 2000, 34, 215-216.	1.4	7